Nuclear medicine

AMR announces addition of Dearborn, Michigan research center

Retrieved on: 
Tuesday, September 19, 2023

DEARBORN, Mich., Sept. 19, 2023 /PRNewswire/ -- Alliance for Multispecialty Research (AMR), a leading integrated research site organization, has opened its newest clinical research center in Dearborn, Michigan.

Key Points: 
  • DEARBORN, Mich., Sept. 19, 2023 /PRNewswire/ -- Alliance for Multispecialty Research (AMR), a leading integrated research site organization, has opened its newest clinical research center in Dearborn, Michigan.
  • AMR has opened its newest clinical research center in Dearborn, MI.
  • "AMR continues to grow its footprint and patient network by providing access to clinical research.
  • AMR is committed to serving patients and research sponsors to drive development of medical cures and treatments of tomorrow," explained AMR Chief Operating Officer Kari Delahunty.

The Inner Circle Acknowledges, Edsa Negussie as a Top Pinnacle Professional for her contributions to the field of Radiology

Retrieved on: 
Friday, September 15, 2023

BLOOMFIELD HILLS, Mich., Sept. 15, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Edsa Negussie is acknowledged as a Top Pinnacle Professional for her contributions to the field of Radiology.

Key Points: 
  • BLOOMFIELD HILLS, Mich., Sept. 15, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Edsa Negussie is acknowledged as a Top Pinnacle Professional for her contributions to the field of Radiology.
  • Dr. Negussie pursued higher education while in Ethiopia at Addis Ababa University where she received a Doctorate of Medicine from the Faculty of Medicine.
  • According to Dr. Negussie, diagnostic radiology is a medical specialty that employs non-invasive imaging modalities to diagnose patients.
  • According to Dr. Negussie, Southfield Radiology Associates provides comprehensive, personalized care with cutting-edge radiology technology.

EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

Retrieved on: 
Saturday, September 16, 2023

Berlin, Germany – 13 September 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to jointly develop a new concept – Satellite Hot Labs (SHLs).

Key Points: 
  • Berlin, Germany – 13 September 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to jointly develop a new concept – Satellite Hot Labs (SHLs).
  • The development of the SHL will allow radiolabeling of cold kits including Gallium-68 PSMA-11 (gallium-68 gozetotide, Illuccix®) for use with RefleXion’s BgRT technology (SCINTIX® therapy).
  • Ga-68 PSMA-11 is currently approved in nuclear medicine for the diagnosis of late-stage prostate cancer and for selection of patients for Lutetium-177 PSMA therapy.
  • “We are pleased to have two experienced partners at our side to jointly lead the SHL project to success.”

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Retrieved on: 
Wednesday, September 13, 2023

These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .

Key Points: 
  • These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .
  • The data show the ability of Molecular Partners to substantially increase tumor uptake of RDT candidates through an adjustment of systemic half-life, achieved by binding to the common blood protein serum albumin.
  • With today’s data we show that tuning of half-life can substantially impact the tumor uptake of our Radio DARPins,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, September 11, 2023

SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two independent studies at the World Molecular Imaging Congress (WMIC) 2023, held on September 5-9, 2023, in Prague, Czech Republic, and the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from September 9-13, 2023.

Key Points: 
  • Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs).
  • The study was carried out by Dr. Dongyoul Lee, an assistant professor at the Korea Military Academy.
  • The dose depositions in tumor and normal organs were estimated based on 203Pb biodistribution data.
  • In addition, tumor progression, survival rates, and body weight changes over a 120-day period were assessed, and favorable radiochemical characteristics were observed.

Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer

Retrieved on: 
Thursday, September 7, 2023

Imaging, for the distribution of PYLCLARI™ (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL), indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography in adults with prostate cancer.

Key Points: 
  • Imaging, for the distribution of PYLCLARI™ (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL), indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography in adults with prostate cancer.
  • Imaging will be responsible for obtaining marketing authorization from Swiss competent authority Swissmedic, and will have exclusive distribution rights for PYLCLARI™ across Switzerland.
  • Imaging has proven to be a crucial supplier for the whole range of Curium's SPECT products for Switzerland.
  • Imaging currently distributes Curium’s entire suite of SPECT imaging products across Switzerland.

Mayo Clinic and GE HealthCare Enter Strategic Collaboration to Advance Innovation in Medical Imaging and Theranostics

Retrieved on: 
Thursday, September 14, 2023

Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.

Key Points: 
  • Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
  • The Strategic Collaboration for Innovation in Medical Imaging and Theranostics comprises Mayo Clinic and GE HealthCare scientists, technology developers, clinicians and other healthcare providers.
  • “Mayo Clinic is globally acknowledged to be among the best in healthcare and care innovation.
  • Collaboration activities and research will take place at Mayo Clinic’s campus in Rochester, Minnesota.

United States Diagnostics Market Research Report 2023-2031: Diagnostics and the Key Role in Enabling Identification, Monitoring, and Management - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 14, 2023

The "United States Diagnostics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Diagnostics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The United States diagnostics market is poised for substantial expansion, projected to achieve a Compound Annual Growth Rate (CAGR) of 5.17% between 2023 and 2031.
  • It encompasses an extensive spectrum of products and services, encompassing diagnostic tests, laboratory equipment, imaging systems, and molecular diagnostics.
  • Diagnostics hold a pivotal role in healthcare, functioning as indispensable tools for identifying, monitoring, and managing various diseases and conditions.

Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer

Retrieved on: 
Monday, September 11, 2023

Results showed that both 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity.

Key Points: 
  • Results showed that both 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity.
  • Therapeutic response and efficacy were evaluated in a preclinical prostate cancer model which showed that 225Ac-rhPSMA-10.1 significantly suppressed tumor growth relative to control.
  • 225Ac-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, and the lead alpha-emitting candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals.
  • IND-enabling studies have been completed and we plan to initiate a Phase 1 clinical study of 225Ac-rhPSMA-10.1 in the first half of 2024.”